RepliCel Awarded US Patent for Injection Device

RepliCel Life Sciences (OTCQB:REPCF, TSXV:RP) received approval from the US Patent and Trademark Office for parts of the company’s multi-needle injection device.
As quoted in the press release:

In the development of propriety cell therapy products targeting pattern baldness (androgenetic alopecia) and aging or sun-damaged skin, RepliCel’s dermatology team identified a need for next-generation dermal injection technologies capable of bringing new levels of precision and control to any substances injected into the skin.
The patent issued by the U.S. Patent and Trademark Office (USPTO) relates to technologies designed to  enable both unparalleled control and repeatable consistency of needle action and product deposition. The patent also relates to the element designed to numb the skin prior to injection with the intended effect of reducing, if not eliminating, the need for local anesthetic prior to aesthetic injection procedures.
The first device being developed under this patent, RCI-02, is designed for injecting soft tissue fillers such as hyaluronic acid (“HA”). According to recent statistics released by the American Society for Plastic Surgery (April 2017), there were over 11 million minimally invasive cosmetic procedures performed nationally in 2016: over 80% were wrinkle treatments and hyaluronic acid filler injections, totalling an expenditure of over $3 billion.¹ RCI-02 represents the nearest-term commercial opportunity for the Company, which it intends to have market-ready and in the hands of a co-development licensee and commercial partner next year (2018).

Click here to read the full press release.

Source: www.newswire.ca